Crossmark

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Crossref DOI link: https://doi.org/10.1016/S0140-6736(23)00774-2

Published Print: 2023-08

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Lee, Siow Ming

Schulz, Christian

Prabhash, Kumar

Kowalski, Dariusz

Szczesna, Aleksandra

Han, Baohui

Rittmeyer, Achim

Talbot, Toby

Vicente, David

Califano, Raffaele

Cortinovis, Diego

Le, Anh Tuan

Huang, Dingzhi

Liu, Geoffrey

Cappuzzo, Federico

Reyes Contreras, Jessica

Reck, Martin

Palmero, Ramon

Mak, Milena Perez

Hu, Youyou

Morris, Stefanie

Höglander, Elen

Connors, Mary

Biggane, Alice M

Vollan, Hans Kristian

Peters, Solange
License Information

Text and Data Mining valid from 2023-08-01

Text and Data Mining valid from 2023-08-01

stm-asf valid from 2023-08-01

stm-asf valid from 2023-08-01

stm-asf valid from 2023-08-01

stm-asf valid from 2023-08-01

stm-asf valid from 2023-08-01
More Information

This article is maintained by: Elsevier

Article Title: First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Journal Title: The Lancet

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(23)00774-2

CrossRef DOI link to the associated document: https://doi.org/10.1016/S0140-6736(23)00807-3

Content Type: article

Copyright: © 2023 Elsevier Ltd. All rights reserved.

Updates are available Erratum dated 2023-08-05

Click to view Erratum: https://doi.org/10.1016/s0140-6736(23)01580-5